Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society of Hematology
2020
|
| _version_ | 1797051470330200064 |
|---|---|
| author | Gerds, AT Savona, MR Scott, BL Talpaz, M Egyed, M Harrison, CN Yacoub, A Vannucchi, A Mead, AJ Kiladjian, J-J O'Sullivan, J García-Gutiérrez, V Bose, P Rampal, RK Miller, CB Palmer, J Oh, ST Buckley, SA Mould, DR Ito, K Tyavanagimatt, S Smith, JA Roman-Torres, K Devineni, S Craig, AR Mascarenhas, JO |
| author_facet | Gerds, AT Savona, MR Scott, BL Talpaz, M Egyed, M Harrison, CN Yacoub, A Vannucchi, A Mead, AJ Kiladjian, J-J O'Sullivan, J García-Gutiérrez, V Bose, P Rampal, RK Miller, CB Palmer, J Oh, ST Buckley, SA Mould, DR Ito, K Tyavanagimatt, S Smith, JA Roman-Torres, K Devineni, S Craig, AR Mascarenhas, JO |
| author_sort | Gerds, AT |
| collection | OXFORD |
| description | PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count <50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts <50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (–3%, −16%, and −27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734. |
| first_indexed | 2024-03-06T18:19:59Z |
| format | Journal article |
| id | oxford-uuid:05f181f4-a3e7-4c71-a9b0-a2176805482c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:19:59Z |
| publishDate | 2020 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:05f181f4-a3e7-4c71-a9b0-a2176805482c2022-03-26T09:00:06ZDetermining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:05f181f4-a3e7-4c71-a9b0-a2176805482cEnglishSymplectic ElementsAmerican Society of Hematology2020Gerds, ATSavona, MRScott, BLTalpaz, MEgyed, MHarrison, CNYacoub, AVannucchi, AMead, AJKiladjian, J-JO'Sullivan, JGarcía-Gutiérrez, VBose, PRampal, RKMiller, CBPalmer, JOh, STBuckley, SAMould, DRIto, KTyavanagimatt, SSmith, JARoman-Torres, KDevineni, SCraig, ARMascarenhas, JOPAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count <50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts <50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (–3%, −16%, and −27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734. |
| spellingShingle | Gerds, AT Savona, MR Scott, BL Talpaz, M Egyed, M Harrison, CN Yacoub, A Vannucchi, A Mead, AJ Kiladjian, J-J O'Sullivan, J García-Gutiérrez, V Bose, P Rampal, RK Miller, CB Palmer, J Oh, ST Buckley, SA Mould, DR Ito, K Tyavanagimatt, S Smith, JA Roman-Torres, K Devineni, S Craig, AR Mascarenhas, JO Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title_full | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title_fullStr | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title_full_unstemmed | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title_short | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis |
| title_sort | determining the recommended dose of pacritinib results from the pac203 dose finding trial in advanced myelofibrosis |
| work_keys_str_mv | AT gerdsat determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT savonamr determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT scottbl determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT talpazm determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT egyedm determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT harrisoncn determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT yacouba determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT vannucchia determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT meadaj determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT kiladjianjj determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT osullivanj determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT garciagutierrezv determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT bosep determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT rampalrk determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT millercb determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT palmerj determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT ohst determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT buckleysa determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT moulddr determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT itok determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT tyavanagimatts determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT smithja determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT romantorresk determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT devinenis determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT craigar determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis AT mascarenhasjo determiningtherecommendeddoseofpacritinibresultsfromthepac203dosefindingtrialinadvancedmyelofibrosis |